The Death of Revlon for the Virtuous: Delaware Chancery Exempts Public Benefit Corporations from the Highest-Bidder Mandate

A Seismic Shift in Delaware M&A Fiduciary Duties

For exactly forty years, the gravitational pull of Delaware corporate law has relentlessly drawn change-of-control transactions toward a single, inescapable mandate: get the highest price for the shareholders. But on July 29, 2026, the Delaware Court of Chancery officially carved out a massive, structural escape hatch. In a first-of-its-kind ruling, the Chancery Court held that directors of Public Benefit Corporations (PBCs) are not legally required to seek the highest reasonable price in a sale of the company.

By effectively ruling that traditional Revlon duties do not apply to PBCs in a change-of-control context, the court has fundamentally altered the M&A playbook. For founders and boards desperate to lock in their company’s mission over pure financial engineering during an exit, the PBC form is no longer just an ESG marketing gimmick. It is now a highly potent structural defense against the ruthless math of the highest bidder.

Escaping the Revlon Zone

To understand the magnitude of this ruling, one must understand the absolute supremacy of Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173 (Del. 1986). Under standard Delaware common law, when a traditional corporation embarks on a transaction that will result in a change of control, the board’s fiduciary duties instantly narrow. As the Delaware Supreme Court famously put it, the directors’ role changes from "defenders of the corporate bastion to auctioneers charged with getting the best price for the stockholders."

For decades, this meant that if a board was selling the company, it could not reject a financially superior offer simply because the buyer had a reputation for stripping assets, firing workers, or abandoning the target's long-term environmental goals. Price was paramount.

But the July 29 Chancery decision confirms what corporate scholars have long theorized but never seen tested in court: the statutory framework governing Public Benefit Corporations preempts the common-law Revlon mandate. Under the Delaware General Corporation Law (DGCL), specifically Del. Code Ann. tit. 8, § 365, PBC directors are explicitly required to balance three competing factors: the pecuniary interests of the stockholders, the best interests of those materially affected by the corporation's conduct, and the specific public benefit identified in the company's certificate of incorporation.

"The court's holding is unambiguous: you cannot force an auctioneer's gavel into the hands of directors who are statutorily mandated to balance purpose with profit. In a PBC sale, mission alignment is a legally valid discount on the purchase price."

What This Means for M&A Practice Today

This ruling is not merely an academic footnote; it is a tactical weapon for dealmakers and a nightmare for traditional M&A plaintiffs. Here is how practice changes immediately:

1. The "Mission-Aligned" Discount is Now Legal: Suppose you represent a PBC target. Acquirer A (a notorious private equity chop-shop) bids $50 per share. Acquirer B (a strategic buyer with a legally binding commitment to the target's environmental mission) bids $42 per share. Under traditional Revlon scrutiny, taking the $42 bid is a near-certain fiduciary breach. Post-July 29, the target board can legally take the lower bid, provided they reasonably determine that the $8-per-share discount is justified by preserving the corporate purpose and protecting key stakeholders.

2. Sell-Side Board Minutes Must Change: Corporate counsel must aggressively adapt their board-level record keeping. If a PBC board is going to accept a lower premium, the minutes cannot rely on vague platitudes about "cultural fit." The board must build a meticulous record demonstrating the § 365 balancing test. Counsel should require financial advisors to provide fairness opinions that expressly account for the preservation of the public benefit, and boards should formally document why a higher bidder poses a material threat to the company's charter-defined mission.

3. Buy-Side Diligence and Pitching: Acquirers targeting a Delaware PBC can no longer rely solely on bullying the board with an overwhelming financial premium. Hostile takeovers of PBCs just became exponentially more difficult. Acquirers must now weave "mission continuation" into their binding transaction documents. If you are buy-side counsel, you need to draft covenants that satisfy the target board's duty to the public benefit, or risk losing the deal to a lower-bidding white knight.

A Death Blow to the Traditional M&A Strike Suit?

For the plaintiffs' bar, this ruling is a massive roadblock. In traditional M&A litigation, alleging that a board failed to maximize short-term value is the bread-and-butter of change-of-control strike suits. But how do you plead a breach of fiduciary duty when the statute explicitly allows the board to sacrifice top-dollar financial maximization for a public benefit?

The standard of review is critical here. Because DGCL § 365 protects PBC directors who make a "reasonable" determination in balancing these interests, courts will likely apply the business judgment rule—or at most, a highly deferential form of enhanced scrutiny—to the board's balancing act. Unless a plaintiff can show that the board's decision was entirely conflicted, made in bad faith, or wholly irrational, motions to dismiss these claims are going to be granted with brutal efficiency.

The Bottom Line

Delaware has always prized private ordering. By refusing to shoehorn Public Benefit Corporations into the 1986 Revlon framework, the Chancery Court has respected the legislature's intent and given teeth to the PBC structure. For founders who care deeply about what happens to their life's work after the closing dinner, converting to a PBC is no longer just a signaling mechanism to attract ESG-focused capital.

It is, as of July 29, the ultimate deal defense. Corporate practitioners must now view the PBC form not as a compliance burden, but as a strategic shield that gives boards the legal cover to say "no" to the highest bidder.